196 results
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
2 Aug 24
VBI Vaccines Provides an Update on its Restructuring Proceedings
4:05pm
personnel due to the distractions and uncertainties, including the Company’s ability to provide adequate compensation and benefits during
8-K
VBIVQ
VBI Vaccines Inc
2 Aug 24
VBI Vaccines Provides an Update on its Restructuring Proceedings
4:05pm
adequate compensation and benefits during restructuring proceedings; the Company’s ability to comply with the restrictions imposed by the DIP Facility
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
30 Jul 24
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
10:28am
the Company’s ability to provide adequate compensation and benefits during the Restructuring Proceedings; the Company’s ability to comply with the restrictions
8-K
VBIVQ
VBI Vaccines Inc
30 Jul 24
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
10:28am
and uncertainties, including the Company’s ability to provide adequate compensation and benefits during Restructuring Proceedings; the Company’s ability
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
29 May 24
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
8:00am
of recurrent glioblastoma. These designations are intended to provide certain benefits to drug developers, including more frequent meetings with the FDA … , and Accelerated Approval and Priority Review, if relevant criteria are met, among other benefits.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI
8-K
EX-1.1
m45r t0ip3gn
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
424B5
arbxo w4p
15 May 24
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
myjc g7lopsc4
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
8-K
EX-4.2
xnu41gwk6so 374
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-4.1
kmfcs8 e2j
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-10.1
8og65a2riflcgio
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
424B5
b85l 0en3q21f
11 Apr 24
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
dex6gopo5bs8ph1a
3 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
8:00am
8-K
EX-99.1
0lcvhy2h7chrfh3390l
20 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
m13u5jc7u uwe
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm